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Abstract 
CK2α is a ubiquitous, well-studied kinase that is a target for small-molecule inhibition, for treatment 
of cancers. While many different classes of ATP-competitive inhibitors have been described for CK2α, 
they tend to suffer from significant off-target activity and new approaches are needed. A series of 
inhibitors of CK2α has recently been described as allosteric, acting at a previously unidentified binding 
site. Given the similarity of these inhibitors to known ATP-competitive inhibitors, we have investigated 
these further. In our thorough structural and biophysical analyses, we have found no evidence that 
these inhibitors bind to the proposed allosteric site. Rather, we report crystal structures, competitive 
ITC and NMR, HDX mass spectrometry and chemoinformatic analyses that all point to these 
compounds binding in the ATP pocket. Comparison of our results and experimental approach with the 
data presented in the original report suggest the primary reason for the disparity is non-specific 
inhibition by aggregation.  
Introduction 
Potent inhibitors of kinases have existed for some time and the majority of these bind in the active 
site of the kinase, competing with the co-factor ATP1,2. Because of the significant conservation of the 
ATP binding site, kinase inhibitors often suffer from poor selectivity3–7. This poor selectivity is a 
disadvantage for several reasons. Firstly, promiscuous inhibitors tend to manifest off-target toxicity if 
used therapeutically and, to combat this, end up being used at suboptimal concentrations8,9. Secondly, 
they are poor chemical tools as they cannot provide unambiguous answers to target validation 
questions. In order to develop more selective inhibitors of kinases, a promising strategy is to target 
sites outside the highly conserved ATP pockets. This leads to increased selectivity as these sites are 
structurally not constrained by the shared property of binding to ATP and therefore tend to be less 
conserved among different kinases10–13. When developing inhibitors that bind outside the primary ATP 
site, it is vital that the new sites are thoroughly validated biochemically, biophysically, and structurally 
to confirm the inhibitor binding mode unambiguously. Often inhibitors are identified as being 
allosteric if they are shown to be non-competitive in biochemical assays. However, this data can be 
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misinterpreted, as non-specific inhibitors also often show similar non-competitive behaviour14. This 
problem can be further compounded by moderate/weak affinity of the hits being investigated, as they 
must be used at higher concentrations, which makes secondary binding more likely. Therefore, 
apparent allosteric behaviour must be very carefully validated to ensure that vital time and resources 
are not wasted on optimising these inhibitors further.    
CK2α has a long history as a target for drug discovery, due to its ubiquitous role in multiple diseases 
such as cancer and fibrosis15–17. CK2α is an unusual kinase in that it is constitutively active and does 
not require phosphorylation for activation18. It is also a highly promiscuous kinase with hundreds of 
recorded cellular substrates.19 Inhibition of CK2α has been achieved mostly through an ATP-
competitive mechanism and a number of high affinity inhibitors of distinctly different chemotypes are 
known and characterized structurally17,20–27. Despite significant effort, most inhibitors have poor 
selectivity, although claims are often made to the contrary28–32. For example, the clinical trial candidate 
CX4945 inhibits at least ten other kinases with nanomolar affinity (see Table S1 in Brear et al.25).  
We have recently demonstrated a new approach to CK2α inhibition.  By using a cryptic so-called αD 
pocket just below the active site as an anchoring point, we have been able to develop highly selective 
inhibitors of CK2α25. The most potent of these is the most specific CK2α inhibitor reported to date, 
CAM406625. The fragment-based development of these inhibitors was supported by a significant 
amount of structural data to identify the optimal αD site anchor moiety and subsequent growth of the 
fragment to the ATP site27. In addition to active site targeting, another approach is the inhibition of 
CK2α binding to its scaffolding partner CK2β. This method has the potential to generate specific 
inhibitors that affect only a subset of CK2 substrates24,33 and has led to some initial encouraging 
success that requires further development24,33,34. 
Recently, a series of CK2α inhibitors (Series A, SI Fig. 1), proposed to bind in a novel site (Site A, SI Fig. 
2) just outside of the highly conserved ATP site, has been published35,36. The authors used enzymatic 
assays, native mass spectrometry and competitive ligand-based NMR studies to characterize the mode 
of inhibition. They interpret their data as supporting an allosteric mechanism. While their data were 
presented as supporting non-ATP-competitive inhibition, there were several reasons why we 
speculated that the mechanism of inhibition by these molecules was not necessarily allosteric. In 
particular: the enzyme assays showed mixed mode inhibition; ATP analogues were replaced in NMR 
studies; high affinity ligands showed unexpected signal in ligand-based NMR experiments; and, 
mutations close to the ATP site affected inhibitory potential 35,36. Our motivation to investigate these 
inhibitors in more detail arose from the somewhat conflicting data presented, 35,36 as well as the 
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chemical properties of these new inhibitors, which are not unlike known ATP competitive kinase 
inhibitors. 
We have used several orthogonal biophysical and structural methods for the characterization of the 
binding mode of these new CK2α inhibitors and we find no evidence for interaction with the proposed 
allosteric site (Site A). We show, using crystal structures, competitive Isothermal titration calorimetry 
(ITC) and NMR, hydrogen-deuterium exchange mass spectrometry (HDX) and computational analyses 
of the ligand structures, that these molecules are clearly binding to the ATP site of the kinase. It thus 
seems likely that most of the inhibitory effect, if not all, comes from traditional type I inhibition of the 
kinase through orthosteric competition with ATP. 
Results 
Chemoinformatic analysis 
The structures of the compounds presented in the original papers and their comparison to other 
validated kinase and CK2α inhibitors raised concerns over the claim that these compounds had a novel 
binding mode. The conserved scaffold of the compounds shares significant similarity to many 
established and well validated kinase inhibitors that bind in the ATP site (Fig. 1)28,37,46–55,38,56–59,39–45. 
This scaffold consists of a central thiazole ring that is connected directly to a phenyl group on one side 
and to a benzoic acid moiety through an amine on the other side (Fig. 1A).  We have used two 
representative compounds from Series A for further investigation, which we denote 1 and 2 (these 
were referred to as 6 and 27 respectively in the original papers35,36). Compound 1 was chosen as much 
of the validation of Series A and Site A relied upon this compound35. Compound 2 was chosen as it was 
the highest affinity inhibitor reported in Series A.36 A search of the Protein Data Bank (PDB, 
http://www.pdb.org) for ligands that bind to serine/threonine kinases (EC=2.7.11.1) and contain a 
benzoic acid group, which is a critical part of the inhibitors in question (Fig. 1B), identified 49 
molecules. Of these, 46 bind in the ATP site and the remaining three bind in interface sites that do not 
exist in CK2α (SI Table 1). Narrowing the search by inclusion of the amine that links the benzoic acid 
to the thiazole ring identified 15 ligands (SI Table 2). Of these ligands, all 15 bind in the ATP site. When 
a similar search was performed on CK2α 14 ligands were identified, all of which bound in the ATP site 
(SI Table 3). Four representative structures of these compounds are shown in Fig. 1C. All of these 
inhibitors display the same binding mode where the binding to CK2α is dominated by the interaction 
between the carboxylic acid and the ζ-amino group of Lys68 (Fig. 1C). Further refining the search to 
include only compounds that also bind in the hinge region, similar in structure to the thiazole-amine 
group of 1, identified eight inhibitors (SI Table 4). These compounds, including CX4945, an extensively 
validated ATP-competitive CK2α inhibitor currently in clinical trials, interact with the hinge and 
Lys6846. Overlaying the 2D structure of 1 with CX4945 shows that 1 could replicate the binding mode 
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of CX4945 (SI Fig. 3) and bind in the ATP site with its carboxylic acid interacting with Lys68 and amine 
hydrogen bonding with the hinge (Fig. 1C). Indeed, modelling of 1 into the ATP site of CK2α replicates 
the crystallographic binding mode of CX4945 (SI Fig. 3). The carboxylic acid is interacting with Lys68 
and an ATP site water as predicted and the hydrophobic core of the molecule is sandwiched between 
Met163 and Val66. The amine is not predicted to interact with the hinge. However, the phenyl group 
is predicted to bind in a similar position to the phenyl chloride of CX4945.   
Further evidence in support of our hypothesis that 1 and 2 may bind in the ATP site comes from the 
analysis of a fragment-based X-ray crystallographic screen against CK2α27 previously performed at our 
lab. One purpose of fragment-based X-ray crystallographic screening is to use the fragments to probe 
the target protein and identify binding hotspots60. From the screen of 354 fragments, 21 were 
identified as binding to CK2α. All 21 bound in the ATP site and interacted with Lys6827. A total of 19 of 
the CK2α-binding fragments were structurally related to 1 and contained a carboxylic acid moiety that 
mediated this interaction (SI Fig. 4). The preference of CK2 for binding ligands with a carboxylic acid 
in this position is further supported by the serendipitous binding of acetate. Acetate ions can be 
utilised as a very low molecular weight probe to identify binding sites for carboxylic acids60. In CK2α 
structures deposited to the PDB, at least nine binding sites for acetate can be identified (SI Fig. 5). 
Among these sites are the Lys68 hotspot in the ATP site, the CK2β interface and the substrate-binding 
pocket. Notably, none of the nine sites overlaps with Site A, the proposed binding site of 1 and 2. 
When such a conserved binding mode is observed for an ATP site-binding pharmacophore, it seems 
unlikely that inhibitors with significant structural similarity would not also bind to the ATP site. These 
observations led us to initiate additional studies to investigate the binding mode of these inhibitors 







Figure 1. Conserved pharmacophore binding in the ATP site of protein kinases (A) The structures of 1 and 2, 
denoted 6 and 27 respectively in the original studies. (B) A summary of the analysis of the established ligands 
that bind to Ser/Thr protein kinases (EC number 2.7.11.1) or CK2α in the ATP site. (C) The structures of the four 
CK2α inhibitors and their protein-bound crystal structures which contain a benzoic acid group that binds in the 
ATP site46,48,56,59.   
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X-ray crystallographic analysis 
The original publication contained no structural data on the inhibitor binding mode. In fact, the 
authors state that ‘cocrystallisation attempts aimed at elucidating the non-ATP competitive binding 
mode of 2-aminothiazole derivatives with CK2α were not successful’35,36. We sought to rectify this and 
have determined structures of both 1 and 2 in complex with CK2α (Fig. 2, SI Table 5). These structures 
were obtained by soaking the compounds into CK2α crystals at 10 mM for 16 hours. The crystals 
diffracted at less than 2 Å resolution and unambiguous positive difference electron density 
corresponding to both 1 and 2 can be clearly seen in the ATP site before the ligands were included 
(Fig. 2A and 2B, SI Fig. 6). As we predicted, the carboxylic acid groups of both compounds interact 
directly with Lys68 like the carboxylic acid of CX4945 (Fig. 2C and 2D). The remainder of the molecules 
however, each have their own binding nuances. The amine of  1 interacts very weakly with the hinge 
region backbone nitrogen of Val116 via a bridging water molecule whereas the OH group of 2 interacts 
with His160, via a bridging water, which pulls the amine of 2  further away from the hinge region and 
prevents interactions with the hinge (Fig. 2C and 2D). The 5-membered rings from 1 and 2 stack on 
top of Met163 which leads to the phenyl and naphthyl ring of 1 and 2 stacking on top of His160 at the 
entrance to the ATP site. The observed binding mode agrees well with the binding mode of established 
ATP site inhibitors of CK2α, such as CX4945. No density corresponding to either 1 or 2 was observed 
in the proposed allosteric binding site (Site A, SI Fig. 6), despite the high concentration of the ligand 
(>1,000-fold excess over KD) used for soaking. The binding mode of 1 in the ATP site of CK2α observed 








Figure 2. Crystal structures of compounds 1 and 2 bound to CK2α (A) The Fo-Fc map (green, displayed 
at 3σ) in the ATP site and Site A before the ligand has been placed. Refined structure of 2 (green) has 
been superimposed on the ATP site (PDB: 6YPJ) and the predicted binding mode of 2 (transparent 
purple) is shown on Site A. (B) The Fo-Fc map (green, contoured at 3 σ) for the ATP site and Site A 
before the ligand has been placed. Refined structure of 1 (blue) has been superimposed on the ATP 
site (PDB: 6YPG) and the predicted binding mode of 2 (transparent purple, from supplementary 
material of reference 34) is shown on Site A. (C) 2 (green) bound to CK2α, (PDB: 6YPJ) with key 
interacting residues and H-bonding highlighted. (D) 1 bound to CK2α (PDB: 6YPG), with key interacting 
residues and H-bonding highlighted. The structure of CX4945 (PDB:3PE1, yellow) has been 
superimposed on the structure of 2 and 1 in panels C and D. Electron densities of the final, refined 
structures are shown in SI Fig. 7.  
 
To reduce the impact that different crystal forms and packing may have on the accessibility of binding 
sites and bias in the resulting complex structure, we have soaked the inhibitors into two different 
crystal forms of CK2α. One is obtained using an engineered form of CK2α (referred to as CK2α 
KKK/AAA) in which lysines 74-76 are mutated to alanines to facilitate crystallization. These lysines are 
in the vicinity of Site A and could affect binding of ligands to this site. However, these lysines do not 
affect the ATP site and we show later that both 1 and 2 bind to CK2α KKK/AAA and to wild type CK2α 
with the same affinity (see ITC measurements). The second crystal form (CK2α SF) has no mutations 
in the lysine-rich loop but has a substrate peptide fused to the N-terminus of the protein, aimed at 
facilitating crystallization. In both crystal forms, we observe electron density for 1 and 2 only in the 
ATP site, and not in the proposed allosteric site (Site A, SI Fig. 6). 
The two crystal forms of CK2α have been extensively used for the determination of CK2α:ligand 
complexes (66 structures currently in the PDB). More than eight different ligand binding sites can be 
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accessed by soaking into these crystal forms (SI Fig. 8), including the proposed allosteric site for 1 and 
2, Site A. We have observed both ADP and GDP bound to Site A in crystal structures of wild type CK2α 
(PDB:6YPN) and in the KKK/AAA mutant (PDB:6YPK) (Fig. 3). The adenosine and guanosine rings sit in 
the hydrophobic pocket identified in the previous modelling work35 and the diphosphate interacts 
with Arg80 that has been identified as an acetate-binding hotspot (SI Fig. 5). This confirms that Site A 
is accessible to ligands in these crystal forms and soaking with 1 or 2 would be expected to result in 
clear electron density in the site, should they bind there. Indeed, ADP can be seen simultaneously in 
both the ATP site and in Site A (Fig. 3D, PDB: 6YPN). The binding conformation of ADP in Site A is very 
different to the conformation in the ATP site (SI Fig. 9). These observations demonstrate that binding 
in Site A does not in itself prevent binding in the ATP site and that if 1 or 2 did bind in both sites, we 
would expect to see density corresponding to it. Furthermore, 1 and 2 would be expected to bind 
predominantly in the highest affinity site and this site would dominate the inhibition.  These crystal 
structures prompted us to perform further experiments to unambiguously establish the binding site 




Figure 3. Crystal structures of ADP and GDP binding to CK2α Site A. (A) GDP binding in Site A. The Fo-
Fc map (contoured at 3σ) centered on the proposed allosteric site. No density was observed in the 
ATP site for GDP therefore the density in the ATP site was not shown for clarity. The CK2α KKK/AAA 
construct was used for this structure (PDB: 6YPK). B) The structure of GDP bound to CK2α, with the 
extensive H-bonding network shown by dotted lines (PDB: 6YPK). C) The proposed binding mode of 1 
(PDB: 6YPJ) superimposed on the structure of GDP bound to CK2α (6PYK). D) The structure of ADP 
bound simultaneously in the ATP site and in Site A of WT CK2α (PDB: 6YPN).  
Hydrogen-deuterium exchange mass spectrometry 
Hydrogen-deuterium exchange (HDX) allows the localization of interaction sites and conformational 
changes in proteins. We have analysed the binding of four different classes of ligands to CK2α (SI Fig. 
10 and 11) using HDX. These ligands were: ADP with Mg2+ and adenosine-5′-(β,γ-imido)triphosphate 
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(AMPPNP)-Mg2+, both of which bind across the entire ATP site interacting with the hinge region and 
Lys68 (SI Fig. 10C and 10D);56  3, which is a fragment that binds only on the right hand side of the ATP 
site, interacting with Lys6856 (SI Fig. 10E); 4, which is an αD site binder (SI Fig. 10G)26 and 6 which links 
the αD site and the ATP site (SI Fig. 10F)27. We recovered 192 shared peptides from each of these HDX 
experiments that redundantly span almost the entire sequence of CK2α (SI Fig. 12). This allows for 
unbiased detection of ligand interaction fingerprints across the whole of the protein. Binding can be 
identified by observing changes in deuterium uptake between CK2α alone and a concurrently run 
ligand-bound sample (SI Table 6). We show all changes greater than ±0.25 Da that have a p-value less 
than 0.01 in a Welch’s t-test (Fig. 4 and SI Fig. 13). Extended data for all peptides and timepoints are 
shown in the Supplementary Information (SI Fig. 13 and a separate spreadsheet). For all the ligands, a 
decrease in deuterium uptake is observed at late timepoints particularly for peptides containing 
residues 54-111 (sample peptides shown in SI Fig. 13). Since this change occurs with all the ligands, it 
appears to result from general stabilization of the region termed the ‘N-lobe’, on ligand binding, rather 
than an effect attributable to a specific site.  
Addition of ADP and AMPPNP-Mg2+ causes clear changes in deuterium uptake in the ATP site (Fig. 4). 
The largest change is a decrease in deuterium uptake for peptides covering residues 39-55 and 121-
131. Residues 39-55 correspond to the P-loop that interacts directly with the phosphates of ADP, while 
residues 121-131 are the αD loop that does not interact directly with ADP or AMPPNP-Mg2+. Protection 
occurs in the latter due to the interaction of the adenosine ring with the hinge region that directly 
links to and stabilizes the αD loop. These observations are similar to those previously observed when 
binding of ATP analogues to other kinases has been studied61,62. The observed decreases in uptake are 
larger for AMPPNP-Mg2+ than ADP-Mg2+ because AMPPNP binds with a higher affinity than ADP. To 
further probe interactions in a more localized area of the ATP site, we used 3 that binds only at the 
right hand side of the ATP site (SI Fig. 10 E), coordinated to catalytic Lys68 (PDB: 5CSP)56 (Fig. 4). With 
3, we see a decrease in deuterium uptake in the P-loop and no change in the αD loop. The pattern of 
protection within the P-loop is also distinct, indicative of different binding contacts being used by 3 
compared to the ATP analogues.  We can thus distinguish binding in the entire ATP site, including 
interaction with the hinge, from binding on just one side where Lys68 is located. 
To ensure we could detect different binding sites with our HDX experiments, we used another well 
characterized ligand (4) that binds to the αD pocket only (SI Fig. 10G)26. This compound shows a 
markedly different HDX fingerprint compared to the ATP analogues and 3 (Fig. 4). The largest 
differences are seen in the αD loop, with binding of 4 resulting in increased uptake compared to 
unbound CK2α. Increased uptake in the αD loop is opposite to the decrease seen upon ADP and 
AMPPNP-Mg2+ binding. This indicates that the binding of 4 in the αD pocket puts the loop in a more 
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flexible or open conformation amenable to exchange, as is seen in the crystal structure of CK2α in 
complex with 4 (PDB: 5ORJ).  Finally, we characterised the HDX fingerprint for 6 that occupies both 
the αD pocket and the ATP site. We observed a similar increase in uptake in the αD loop as with 4 (Fig. 
4). Compounds 4 and 6 also cause decreased uptake in the P-loop, with 6 showing more protection 
than 4, similar to the protection we observed with 3.  
All these fingerprints are consistent with the known binding modalities of these ligands to CK2α and 
can be used to identify the binding modes of new compounds. We performed the same experiments 
to characterise the binding of compound 1 to CK2α (Fig. 4). Addition of 1 to CK2α causes decreased 
uptake in the P-loop with a pattern and magnitude of change similar to the addition of AMPPNP-Mg2+. 
However, no changes are observed in the αD pocket, as was observed with the addition of 3. These 
results are consistent with the binding mode seen in the crystal structures where 1 makes significant 
hydrogen bonding just to Lys68 with only weak water-mediated interaction to the hinge region. These 
data do not allow us to unequivocally eliminate binding at the proposed allosteric site. However, if the 
allosteric binding mode were correct, two clear differences would be expected. Firstly, a change in the 
uptake by residues 67-88, part of Site A, would be expected due to the main interaction being with 
the acidic group of 1 (SI Fig. 10). We do not observe changes in uptake in this region despite it being 
redundantly covered by eight peptides (SI Fig. 13). Secondly, no change in the uptake by the P-loop 
would be expected since the modelling does not predict significant interactions with that part of the 
protein. Interactions with the P-loop, such as that seen for 1, are one of the major features of ATP site 






Figure 4. HDX analysis of ligand binding to CK2α. Heatmaps show the change in deuterium uptake 
upon binding of different ligands to apo CK2α. Each panel, with the ligand listed on the top, shows the 
heatmaps for 10 s and 100 s time points for peptides corresponding to the P-loop and αD-loop, in 
comparison to unliganded CK2α. All depicted changes are greater than ±0.25 Da and have a p-value 
less than 0.01 in a Welch’s t-test. The exact start and end residues for each peptide are shown on the 
left of the panels. Next to each heatmap are two graphs showing deuterium uptake for one peptide 
from each P-loop (top) and αD loop (bottom) for apo CK2α (black) and CK2α with ligand (grey). The Y-
axis range is 80% of max D-uptake assuming the N-terminal residue undergoes 100% back-exchange. 
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Data have not been corrected for back-exchange. Error bars are ±2σ derived from three technical 
replicates. A structural diagram in between the uptake plots has the P-loop and αD loop coloured 
purple and green, respectively, and the bound ligand in surface rendering in yellow. Full HDX data are 
shown in SI Fig. 13 and available in the supplementary spreadsheet.  
Ligand-observed NMR analyses 
To further explore the binding of the new compounds to CK2α, we have used various ligand-based 
NMR methods, similar to the experiments in the original characterization of these molecules. We were 
particularly concerned about the evidence for the simultaneous binding of CX4945 and 1 due to the 
presence of strong signals for CX4945 in the STD NMR spectra. In order to observe a signal in an 
saturation transfer difference (STD) spectrum, the saturation of protein resonances has to be 
transferred to the bound ligand, which then dissociates to join the pool of bulk ligand in solution 
before it can be detected. This means that the size of the signal for a given ligand is proportional to 
the amount of the ligand that binds to and is released by the protein during the saturation step of the 
STD experiment. Therefore, ligands with relatively fast association (kon) and dissociation (koff) rates 
give the largest signal63,64.  
We have determined the off rate of CX4945, that binds to CK2α with low nanomolar to picomolar 
affinity46, from CK2α to be 0.0039 s–1 by SPR (SI Fig. 14). When ligands have koff rates <0.1 s–1, the 
saturation cannot be transferred effectively to bulk ligand in solution resulting in no observable STD 
effect64. The experimentally determined off-rate for CX4945 means that less than 1% of CX4945 would 
have dissociated after the 2-second saturation time used in the NMR pulse sequence. This would mean 
that the concentration of saturated ligand in solution would be less than 0.1 μM. This difference would 
not be observable by NMR.  
To resolve these issues, we have repeated the STD NMR studies reported in the original publication 35 
and used two additional ligand-based NMR experiments, Carr-Purcell-Meiboom-Gill (CPMG) and 
Water-LOGSY63,  for further validation. Our STD experiment shows that 1 binds to CK2α, as revealed 
by detectable transferred 1H intensities (Fig. 5A(i)). However, when the same experiment is run in the 
presence of CX4945, a significant reduction of the STD signals from 1 are observed, indicating direct 
competition between the two ligands (Fig. 5A(ii)). In the original paper, strong CX4945-derived signals 
are also clearly visible. The signals - which are comparable in magnitude to the much weaker binding 
ligand 1 - could instead arise from non-specific binding of CX4945 to lower affinity sites on CK2α (as 
was shown by native mass spectrometry35), precipitation of CX4945 leading to false positive signals in 
the experiment or binding of CX4945 to soluble aggregates of 1. 
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Given the disparity in the STD NMR experiments between our results and those in the original report, 
we have also used CPMG and Water-LOGSY experiments. These exploit different NMR phenomena 
(relaxation rates, transfer of saturation) to observe the binding of the ligand to the protein63. Using 
three different methods to observe the binding of the ligand reduces the chance of experimental 
anomalies interfering with the outcome of the experiment. The Water-LOGSY experiment shows clear 
binding of 1 to CK2α and complete inhibition of binding in the presence of CX4945 (Fig. 5B). Similarly, 
in the CPMG experiment, an increase in the signal from the aromatic protons of 1 was observed in the 
presence of CX4945 indicating a reduction in binding of 1 to CK2α (Fig. 5C). In conclusion, all three 
ligand-observe NMR experiments show binding of 1 to CK2α and in all three experiments binding is 
abolished by CX4945, suggesting direct competition between these two ligands as they bind to the 





Figure 5. Ligand-based NMR experiments to detect binding of 1 to CK2α and competition by CX4945. 
All panels are overlays of spectra recorded in the presence (black) and absence (green) of CK2α. (A) 
Saturation Transfer Difference (STD) 1H spectra of 1 (i) in the absence of CX4945, and (ii) in the 
presence of 50 μM CX4945. (B) WaterLOGSY spectra of 1 (i) in the absence of CX4945, and (ii) in the 
presence of 50 μM CX4945 (ii). (C) Relaxation-edited (CPMG) 1H spectra of 1 (i) in the absence of 
CX4945, and (ii) in the presence of 50 μM CX4945 (ii).  (NB: the signals at ca. 7.7 ppm are in fact two 
overlapping doublets and therefore small changes to either chemical shift results in an apparent 
change to the multiplet structure.) 
16 
 
To further confirm the validity of our results, we repeated the CPMG NMR study using the lower 
affinity ligands 3, 5 and CAM4066 as competitors (SI Fig. 15). 3 is a small, low affinity ligand in the ATP 
site and as such it is less likely to have an allosteric affect that might prevent binding at the adjacent 
Site A – an argument that could explain inhibition of binding to 1 in the presence of CX4945. Therefore, 
the reduction in the binding of 1 in the presence of 3 (SI Fig. 14B) is a more convincing proof that 1 is 
binding in the ATP site. CAM4066 links the ATP site and the αD site and, as predicted, reduces the 
binding of 1 to CK2α (SI Fig. 15C). To rule out binding of 1 to the αD site, we have also used 5, an 
optimized fragment with high affinity for the αD site. This should not prevent binding in the ATP site. 
Indeed, ligands similar to 5 have been shown to bind simultaneously with ATP site fragments by X-ray 
crystallography  (PDB:6EHK)26. As predicted, and unlike with CX4945, 3 and CAM4066, the αD site 
ligand 5 has no effect on the binding of 1 to CK2α (SI Fig. 15D). Similar CPMG and STD NMR 
experiments were performed with the CK2α KKK/AAA mutant with the same outcomes (SI Fig. 16 and 
17).  These results further demonstrate that 1 binds in the ATP site.  
Isothermal titration calorimetry  
As a final confirmation, we have used isothermal titration calorimetry to determine affinities of 1 and 
2 to CK2α and to evaluate the effect of competing ligands and CK2α mutations. This process has been 
successfully used to verify the binding site of novel CK2 inhibitors that bind in the αD site26.  The 
affinities of compounds 1 and 2 for CK2α were determined to be 22 μM and 2.2 μM respectively (Fig. 
6A and C). When the same experiments were performed in the presence of saturating concentrations 
of CX4945, no binding of either compound to CK2α was observed (Fig. 6B and 6D). This observation is 
in line with all our previous data and suggests that compounds 1 and 2 bind in the same site as CX4945. 
We also performed the experiment with 2 in the presence of CAM4066, which competes with ATP, 
but uses only a small benzoic acid moiety to interact with the ATP site, deriving most of its binding 
energy from the αD pocket. CAM4066 abolished the binding of 2 to CK2α (SI Fig. 18). In the modelling 
of the binding of 1 and 2 reported previously35,36, Lys74 was proposed to form a vital part of the binding 
site and to interact with the carboxylic acid of 1 and 2. Therefore, mutations to this residue should 
reduce the affinity of 1 and 2 for CK2α. To test this, we repeated the ITC experiments using the 
construct CK2α KKK/AAA, in which three adjacent lysine residues (Lys74-76) have been mutated to 
alanine. These mutations had a negligible effect on the affinity of 1 or 2 for CK2α as we determined 
near identical affinities of 27 μM and 3.3 μM, respectively (SI Fig. 18). The binding of 1 and 2 to CK2α 
KKK/AAA was also fully inhibited by the presence of CX4945 and CAM4066 respectively (SI Fig. 18). 
These results are further evidence that the ATP site, not the proposed allosteric site, is the primary 




Figure 6. ITC measurement of binding of 1 and 2 to CK2α. (A) Titration of 1 into 10 μM CK2α Titration 
of 2 into 10 μM CK2α. (B) Titration of 1 into 10 μM CK2α Titration of 2 into 10 μM CK2α in the presence 
of CX4945 (C) Titration of 2 into 20 μM CK2α. (D) Titration of 2 into 20 μM CK2α in the presence of 
100 μM CX4945. 
Discussion 
We present compelling and consistent evidence that 1 and 2 bind in the ATP site of CK2α, not in Site 
A, as was previously proposed.35,36  We see no evidence for binding in Site A. This is as expected, based 
on our analysis of the structural data of similar kinase inhibitors. In the original study of Series A,36 five 
main pieces of evidence were used to verify a novel binding mode. This evidence included: competitive 
native mass spectroscopy studies, ligand-based NMR, thermal shift analysis and biochemical assays. 
While we were preparing this manuscript for publication, the Niefind group published their analysis 
of the same series of compounds, which also showed binding to the ATP site by X-ray crystallography.65 
While they have not done other biophysical analyses on the binding, they do show by enzymatic assay 
that these inhibitors are ATP competitive, consistent with our data.   
One of the cornerstones of the theory of allosteric inhibition was the observation that that CX4945 
binds CK2α simultaneously with 1, and that 1 competes with inositol hexaphosphate (IP6, phytic acid), 
shown by mass spectrometry. The data presented indicate that at least three molecules of 1 bind to 
CK2α. In the presence of CX4945 this is reduced to two binding sites, but no data were presented to 
confirm the identity of these sites in which 1 was binding when it bound simultaneously with CX4945 
(for example mutational studies combined with native mass spectrometry). Some of these sites are 
expected to be non-specific, low affinity sites and the mass spectrometric data does not confirm which 
is the primary binding site of 1. The first evidence presented for the location of the binding site of 
these compounds is the observation that in the presence of 1 the complex between IP6 and CK2α is 
not observed in the native mass spectra. This led to the theory that 1 binds in the proposed site as a 
crystal structure was published by Lee et al (PDB:3W8L)37 of IP6 apparently binding to CK2α in this site. 
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However, the binding site of IP6 presented in that crystal structure is more controversial than is 
discussed in the publication37. In this structure, IP6 is found at a crystal contact where half of the site 
is composed of residues from a symmetry related CK2α molecule in the crystal lattice (SI Fig. 19). 
Therefore, IP6 could in theory bind to both these sites. From this crystal structure the binding site 
could be located around Lys74 or His276. However, as the site is only fully formed in a crystal lattice 
(SI Fig. 19), IP6 may not in actual fact bind to CK2α at either of these sites in solution. IP6 is also seen 
to bind weakly at a site centered on His236 in several other crystal structures (PDB:5OQU, 5ORJ, 5MPJ, 
5CVH)26,27,56. The native mass spectrometric competition studies with CX4945 or IP6 do not therefore 
unambiguously confirm the binding mode of 1.  
Another cornerstone of the allosteric site binding was the observation of the binding by ligand-based 
NMR and simultaneous detection of CX4945 binding, interpreted as lack of competition. As discussed 
before, a high affinity ligand like CX4945, with slow dissociation rate should not yield detectable signal 
in these experiments.  The binding of CX4945 observed in those STD experiments is however more 
likely to be due to an artefact in the experimental setup. This could be through a number of 
mechanisms including aggregation of the ligand or binding to non-specific lower affinity binding sites 
outside the ATP site.66 These lower affinity sites would have higher on/off rates than the ATP site and 
therefore show a larger signal in the STD spectrum. Non-specific and low affinity sites can have a 
confusing influence on competition studies. This is a particular problem with the NMR studies as 
ligand-observed NMR is optimized for studying low affinity sites and requires ligands with rapid on/off 
rates in order for the signal (and therefore binding) to be observed. Therefore, blocking the primary 
(high affinity) site may not remove the binding signal arising from other sites. The competition studies 
in the original papers were done at 500 μM ligand concentration, well beyond the observed affinities 
or Kis of 1 and 2 and in a range where non-specific binding would be more likely to occur.35,36 The 
binding signals observed for CX4945 in the STD spectra cast some doubt on the conclusions drawn 
about the simultaneous binding of 1 and CX4945. This is because the signals observed for CX4945 
cannot be due to binding in the ATP site as the dissociation rate for this site is too slow. The major 
difference between our experimental system and the system reported in the literature is the DMSO 
content. In brief, in the procedure reported here stocks of 1 and 2 were made in d6-DMSO and diluted 
20-fold in the buffer. This was done to ensure the ligands were fully soluble in the experiment and led 
to a final d6-DMSO content of 5% (which was also used to provide the field-frequency lock signal). 
When we first attempted to run the experiment without DMSO, we observed precipitation of the 
ligands.  As aggregation can lead to false positives in STD experiments it was decided to use DMSO in 
all our experiments.66 However, in the original experiment D2O was used for the lock and no DMSO 
was used to solubilise the ligand. The difference in the solvent conditions may mean that 1 and 2 were 
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closer to the limits of their solubility in the original experiments and thus more likely to form 
aggregates. Aggregates are common causes of false positives in biochemical assays and are often 
missed as they may not be easily visible to the naked eye.  These aggregates may lead to the signals 
observed in the STD for CX4945 and 1.  
The biochemical assays performed previously showed that the compounds exhibited mixed mode 
non-competitive behavior and led to the understandable conclusion that they do not bind in the ATP 
site. However, this is contradictory to the binding mode we see in the crystal structures. A proposed 
explanation for the non-competitive inhibition observed in the assay comes from the thermal stability 
data also presented in the original paper.35 The data show that the thermal stability of the proteins 
decreases in the presence of 1 and 2. This thermal de-stabilization could be due to a number of 
different mechanisms caused by specific and non-specific effects. These mechanisms include; breaking 
up of protein complexes by specific binding to the protein; binding to the unfolded or partially 
unfolded protein; the formation of aggregates that bind the protein and unfold it and specific binding 
that traps the protein in a less stable conformation67–70.    
It is impossible that the first mechanism is operating in this example as CK2α is present as a monomer. 
The other mechanisms however may explain the conflicting results presented. All proteins exist in an 
equilibrium between the native and unfolded form of the protein.71 For the majority of ligands, the 
ligand binds to the native form of the protein which stabilizes the folded form leading to a positive 
thermal shift. If the ligand binds to the unfolded or partially unfolded form of the protein and stabilize 
the unfolded form this could lead to a destabilization of the protein. This would in turn lead to a 
decrease in the Tm. Binding to the unfolded protein can occur by two mechanisms, the first mechanism 
is by the formation of colloidal aggregates of the small molecules, onto which the protein would then 
be sequestered.70 The aggregates are hydrophobic and preferentially bind the unfolded or partially 
unfolded form of the protein where the hydrophobic core is exposed. Therefore, a negative shift in 
the Tm is observed. This is one of the most common forms of non-specific inhibition that plague 
biochemical assays and would be seen in assays as noncompetitive inhibition. The second mechanism 
occurs when the ligand monomers bind to a partially unfolded or fully unfolded form of the protein 
stabilizing that form. It may be possible for the binding to the partially unfolded form to be a specific 
form of inhibition. 
Modelling experiments proposed Site A as the binding site for 1 and 2 (SI Fig. 1)35. We have 
accumulated extensive evidence that these compounds bind in the ATP site. However, Site A as a 
general ligand binding site has been verified by our structures of ADP and GDP bound in this location.  
This suggests that Site A could be utilized for the development of novel inhibitors of CK2α and it also 
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demonstrates that this site is accessible for ligand binding in our crystal forms. If this site were to be 
successfully targeted by inhibitors, it would require extensive structural and biochemical validation to 
confirm that compounds are really binding in the new site and not in one of the several known small 
molecule binding sites in CK2α. 
Conclusions  
We believe that the data we have presented here leads to the conclusion that the compounds 
represented by 1 and 2 bind to the ATP site and will inhibit CK2α via an orthosteric, ATP-competitive 
mechanism. This diverse set of data pointing to 1 and 2 binding at the ATP site includes multiple crystal 
structures, competitive ITC studies, competitive NMR studies, HDX mass spectrometry and 
computational analyses of the ligand structures. We also believe that the evidence presented 
previously in support of an allosteric mode of inhibition for these compounds may have been distorted 
by non-specific binding of the compounds to CK2α, which in turn affected the interpretation of 
competition data with CX4945.   
Experimental Section 
Modelling 
Modelling of binding of 1 and 2 to CK2α was done using the GOLD software package (CCDC) using the 
structure from PDB entry 3PE1 as the target. The site of interest was defined as a 20 Angstrom sphere 
around the ligand CX4945, which includes both the ATP site and the proposed allosteric site. Ligand 
files were generated with grade (Global Phasing). The conserved water interacting with Lys68 was 
included but no other waters. The ChemPLP scoring system (CCDC) was used to rank the results. 
Coordinates of the modelling results are included as supplementary files.  
Expression and purification 
Expression and purification of CK2α (wild type, KKK/AAA and SF) was done as described before56. For 
the surface plasmon resonance experiments a new construct carrying two His-tags, one at the N-
terminus and one at the C-terminus was created. CK2α was amplified by PCR using primers “AGCTA 
GAATTCGGAGAAGGCGAGGGTAGTGAAGGCCCCGTGCCAAGCAGGGCCAGAGT” and 
“ATACTCAAGCTTAATGGTGATGGTGATGGTGGGAACCCTGGAAGTACAGGTTTTCCTTCACAACAGTGTA 
GAAATAGGGGTG”. The resulting fragment was digested with EcoRI and HindIII restriction enzymes 
and ligated into a pHAT4 vector digested with the same enzymes. The sequence of the protein that 
the resulting construct (pHAT4_CK2-TEV-L-His) encodes for is shown below with His-tags (bold) and 








Expression of this protein was done as with other CK2α construct, using the BL21(DE3) strain of E. coli.  
Single colonies of the cells were grown in 6 l 2xTY with 100 μg/mL ampicillin at 37 °C until OD600 of 0.6 
after which 0.4 mM IPTG was used to induce expression. After three hours of culturing at 37 °C the 
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cell were harvested by centrifugation at 4,000 g for 20 minutes. The cells were resuspended in 20 mM 
Tris pH 8.0, 500 mM NaCl and lysed using an Emulsiflex C5 homogeniser. DNaseI was added to aid with 
digestion of E. coli genomic DNA and protease inhibitor tablets we are added to minimise proteolytic 
degradation. Following centrifugation for 30 min at 15,000 g, the clarified supernatant was loaded 
onto 4 ml Ni2+-NTA agarose column and washed with the lysis buffer, followed by 20 mM Tris pH 8.0, 
500 mM NaCl, 20 mM imidazole and the protein eluted with 20 mM Tris pH 8.0, 500 mM NaCl, 300 
mM imidazole. Peak fractions, as analysed by SDS-PAGE, were pooled together and dialysed overnight 
against 4 l of 20mM Tris pH 8.0, 500 mM NaCl at +4°C. The dialysed sample was diluted to ~65 mM 
salt concentration in two batches and immediately loaded onto HiTrapQ HP column to minimise 
aggregation in low ionic strength. CK2α was eluted using a linear salt gradient.  Peak fractions of each 
of the two chromatographic steps were pooled, concentrated to ca. 5 ml in volume and purified with 
size exclusion chromatography on a Superdex 75 16/60 HiLoad column using 20 mM Tris pH 8.0, 500 
mM NaCl buffer. Peak fractions were pooled, concentrated to ca. 10 mg/ml using Vivaspin 20 5000 
MWCO centrifugal concentrators and flash frozen in small aliquots.  
Source of compounds 
The synthesis of Compound 1 and Compound 2 was described previously by Bestgen et al35,36. Purity 
was determined as >95% by LC-UV. Compound 1 was also purchased from enamine (ID:Z2239047232, 
no longer available). Purity was determined as >95% by LC/MS. CX4945 was purchased from 
Cambridge bioscience (HY-50855B-5mg) purity was determined as >99% by HPLC. ATP was purchased 
from Sigma Aldrich (Cat: A7699). The purity was determined as >99% by HPLC. GDP was purchased 
from Sigma Aldrich (G7127). The purity was determine as >96% by HPLC. 
X-ray crystallography   
Crystallisation, soaking of ligands and structure determination was done as described before56.  X-ray 
diffraction data were collected at the Diamond Light Source and data from automated data processing 
with autoProc were used for the structure determination. Fo-Fc electron density maps for all the 
ligands, calculated prior to ligand placement in the model, are shown in Supplementary Figure 5 and 
the final densities, as calculated by PDB AutoDep software, are shown in Supplementary Figure 6. All 
coordinates have been deposited to the Protein Data Bank under accession numbers 6YPG, 6YPH, 
6YPJ, 6YPK, 6YPN. We will release the atomic coordinates and experimental data upon article 
publication.  Data collection and refinement statistics are shown in Supplementary Table 5.  
Hydrogen-deuterium exchange mass spectrometry 
Stocks of 25 μM CK2α with and without ligand were prepared in 20 mM Tris-HCl, 500 mM NaCl, pH 
8.0 at 25°C. In some experiments a small percentage of organic solvent was added to increase 
solubility. Variations and ligand concentrations are noted in Supplementary Table 6. Stocks were 
equilibrated at 4°C for 10 minutes and then diluted 1:24 with the same buffer containing H2O for 
controls (pHread=8.0 at 25°C) or D2O (final D2O of 96% (v/v) with pHread=7.6 at 25°C). After 10 s, 102 s, 
103 s, 104 s, and 105 s, samples were mixed 1:1 with 0.8 % formic acid, 1.6 M guanidinium chloride, pH 
2.3 to give a final pH of 2.6 at 0 °C, and flash frozen in liquid nitrogen for storage at –80°C. Samples 
were thawed and LC-MS performed using a Waters HDX manager and SYNAPT G2-Si Q-Tof. Three 
technical replicates of each sample were analyzed in a random order. Samples were digested online 
by Sus scrofa Pepsin A (Waters Enzymate BEH) at 15°C and peptides trapped on a C18 pre-column 
(ACQUITY UPLC Peptide BEH C18 VanGuard Pre-column) for 3 min at 100 μL/min and 1°C. The LC buffer 
was 0.1% formic acid. Peptides were separated over a C18 column (Waters acquity UPLC BEH) and 
eluted with a linear 3-40% (v/v) acetonitrile gradient for 7 min at 40 μL/min and 1°C. Raw data of 
control samples were processed by PLGS (Waters Protein Lynx Global Server 3.0.2) using a database 
containing Sus scrofa Pepsin A and Homo sapiens CK2α. In PLGS, the minimum fragment ion matches 
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per peptide was 3, and methionine oxidation was allowed. The low and elevated energy thresholds 
were 250 and 50 counts respectively, and overall intensity threshold was 750 counts. Labelled data 
were analyzed in DynamX 3.0 with peptide filters of 0.3 products per amino acid and 1 consecutive 
product. All mass spectrometry data were acquired using positive ion mode in either HDMS or HDMSE 
modes. HDMSE mode was used to collect both low (6V) and high (ramping 22-44 V) energy data-
independent peptide fragmentation data for peptide identification. HDMS mode was used to collect 
low energy ion data for all deuterated samples. All samples were acquired in resolution mode. 
Capillary voltage was set to 2.8 kV for the sample sprayer. Desolvation gas was set to 650 L/hour at 
175°C. The source temperature was set to 80°C. Cone and nebulizer gas was flowed at 90 L/hour and 
6.5 bar, respectively. The sampling cone and source offset were both set to 30 V. Data were acquired 
at a scan time of 0.4 s with a range of 100-2000 m/z. Mass correction was done using [Glu1]-
fibrinopeptide B as a reference mass. To allow access to the HDX data of this study, the HDX data 
summary table (Supplementary Table 6) and the HDX data table are available online per consensus 
guidelines72. 
Ligand-observe NMR experiments 
In the control experiment a stock solution of 2.5% DMSO-d6, 7 μM CK2α WT in 0.5mM Tris, 200 mM 
NaCl, pH 8.0 was prepared. This was split into two samples. Ligand in DMSO-d6 or DMSO-d6 alone was 
added to each such that one sample contained 5% DMSO-d6 with a total volume of 180 μL, and the 
second sample contained 5% DMSO-d6 and 500 μM 1. In a typical competition experiment a stock 
solution of 50-500μM competing ligand, 2.5% DMSO-d6, 7 μM CK2α WT in 0.2mM Tris, 100 mM NaCl, 
pH 8.0 was prepared. This was again split into two samples. One sample contained 5% DMSO-d6 and 
50-500 μM competing ligand with a total volume of 180 μL. The second sample contained 5% DMSO-
d6, 500 μM 1 and 50-500 μM competing ligand. 
NMR data were recorded at 300 K with a Bruker AVANCE spectrometer operating at 500 MHz and 
equipped with a room-temperature probe. CPMG-filtered 1D 1H experiments 73 were run with 600 
loops of length 1 ms. Water suppression was achieved with low-power presaturation and DPFGSE 
WATERGATE W5 74,75. Saturation transfer difference (STD) experiments 76 were acquired with 2 s of 
alternating on- and off-resonance saturation (20 ms Gaussian pulse, +0.8 and –5 ppm), a T1ρ filter to 
suppress protein signals, and DPFGSE WATERGATE W5. WATER-LOGSY experiments 77 were recorded 
using a 20 ms Gaussian to invert the water resonance, a mixing time of 1.2 s, a T2 filter to suppress 
protein signals, and DPFGSE WATERGATE W5. 
Isothermal calorimetry  
ITC All ITC experiments were performed at 25 °C using a MicroCal iTC200 instrument (GE Healthcare). 
CK2αWT (20 mg/mL, 20 mM Tris pH 8.0, 500 mM NaCl) was diluted in Tris buffer (200 mM Tris, 300 
mM NaCl, 10% DMSO) and concentrated to 20-50 μM. Compounds in 100x stock solutions were 
diluted into the buffer ensuring that the DMSO concentrations were carefully matched. In a typical 
experiment CK2αWT (10 μM) was loaded into the sample cell and 0.4-2.0 mM of the ligand was 
titrated in eighteen 2 μL injections of 2 s duration at 150 s intervals, stirring at 750 rpm. Heats of 
dilution were determined in identical experiments, but without protein in the cell.  The data fitting 
was performed with a single site binding model using the Origin software package. 
Surface Plasmon Resonance 
An Ni-NTA sensor chip (GE Healthcare) was activated with 0.5 mM NiCl2, 0.2 μM CK2 with both N- 
and C-terminal His-tags was immobilised onto the activated Ni-NTA sensor chip in 20 mM Tris pH 8.0, 
500 mM NaCl. Binding of CX4945 was determined in 0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.05% v/v 
TWEEN 20, 0.5% DMSO at five different concentrations (15 nM, 10 nM, 5 nM, 1 nM and 0 nM). The 
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chip surface was regenerated with an initial wash of 500 mM EDTA followed by 4 M guanidinium 
chloride, 250 mM EDTA, 50 mM NaOH. The reference channel was activated with 0.5 mM NiCl2. All 
data were processed using the manufacturer’s BIAevaluation software. 
Ancillary Information 
Additional figures are available free of charge via the Internet at http://pubs.acs.org 
Structural coordinates in Protein Data Bank: 
6YPG (CK2α in complex with 2), 6YPH (CK2α in complex with 2), 6YPJ (CK2α in complex with 1), 6YPK 
CK2α in complex with GDP), 6YPN (CK2α in complex with ATP). 
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